We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
Collaboration, Press Release
More safety for seniors at home with a contactless fall detection solution
Big congratulations to Sedimentum, who has launched a contactless emergency product for Swiss
households: “SAFE-living”, the intelligent fall detection service. An innovative solution that
doesn’t require wearing a bracelet or pressing an emergency button.
Press Release, Regulatory
HEMEX is ISO 9001:2015 and ISO 13485:2016 Quality Management System certified
This milestone shows the devotion of our QA team to ensuring HEMEX’s high standards and commitment to quality. Achieving this certification was one of the milestones we wished to accomplish in 2022.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
Only six months after closing its seed round of CHF 2.1 million, the successful healthtech start-up closes its pre-series A financing round of CHF 3.3 million. With this new capital, Sedimentum intends to conquer the Swiss B2C market with its intelligent SAFE-living solution.
Collaboration, Press Release
Resistell AG announces completion of clinical pilot Performance Evaluation Study
We’re delighted to announce that our portfolio startup Resistell AG has completed the pilot phase of its clinical Performance Evaluation
Study (PES) with 100% accuracy and at least 7 hours shorter time-to-result (TTR) compared to gold standard methods.
HEMEX is pleased to announce the successful completion of another fundraising round. Following an oversubscribed first closing in February, our second closing of the Series C increased the round to CHF 7.1 million.
We’re delighted to announce a new collaboration between HEMEX and The Bioinformatics CRO which will provide an even more complete CRO service for our start-ups! Find out how this collaboration can support you throughout your Clinical Development phase.